Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
SeriousFun Children's Network Appoints Denise Bailey-Castro and Camilla Castro…
"Denise and Camilla bring exceptional leadership experience and a shared passion for empowering young people," said Blake Maher, CEO of SeriousFun Children's Network. "Their strategic insight and commitment to children facing health challenges will strengthen our mission and the lasting impact we deliver to children around the world." "Denise and Camilla bring exceptional leadership experience and a shared passion for empowering young people," said Blake Maher , CEO…
PR Newswire
14/11/2025
Cornerstone Robotics Closes Oversubscribed New Financing Round of Approximately…
With its industry-leading technologies and strong growth potential in the field of surgical robotics, Cornerstone Robotics has attracted a global strategic investor in this financing round. The Company also welcomed some global institutional or sovereign wealth funds, whose participation will further support Cornerstone Robotics' market access and strategic partnerships globally. Existing shareholders have also increased their investment, reaffirming their strong confidence in the Company's…
PR Newswire
14/11/2025
Fondazione Telethon announces CHMP positive opinion for Waskyra™, a gene therapy…
Developed through decades of research at theSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget)inMilan, the therapy represents a major scientific and clinical achievement, offering new hope for patients affected by this condition. "This milestone demonstrates that academic research, when guided by a strong sense of responsibility towards patients and conducted to the highest industrial standards, can truly change the natural history of rare diseases," said Ilaria...
PR Newswire
14/11/2025
Medical Device Plastics Market worth $31.82 billion by 2030 - Exclusive Report…
220 - Tables90 - Figures255 - Pages 220 - Tables 90 - Figures 255 - Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122410426 The growth of the medical device plastics market is being propelled by a combination of technological, demographic, and regional factors. Global healthcare spending, expanding medical device manufacturing base, and rapid adoption of advanced, diagnostic, and therapeutic technologies are driving consistent demand for...
PR Newswire
14/11/2025
Cardiovascular Biologics Market Expected to Reach USD 4.23 Billion by 2033 Amid…
Growth Drivers: Innovation Meets Unmet Clinical Need Growth Drivers: Innovation Meets Unmet Clinical Need Download PDF Brochure:https://www.datamintelligence.com/download-sample/cardiovascular-biologics-market Browse in-depth TOC on "Cardiovascular Biologics Market" 70 – Tables 66 – Figures 195 – Pages Market Segmentation Analysis By Biologic Type The market is categorized intoMonoclonal Antibodies (mAbs),siRNA-Based Therapeutics,Recombinant Proteins...
PR Newswire
14/11/2025
Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 14 November 2025 - Today, Novo Nordisk A/S held its Extraordinary General Meeting, which was convened to elect new members of the Board of Directors.At the Extraordinary General Meeting, Helge Lund (chair), Henrik Poulsen (vice chair) and the Board members Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay stepped down from the Board of Directors. Resolutions adopted at the Extraordinary General Meeting ElectionsElection of Lars...
Nasdaq GlobeNewswire
14/11/2025
Alkermes Response to Avadel Announcement
Terms used but not defined in this announcement have the same meaning given to them in the Transaction Agreement entered into between Alkermes and Avadel (the "Transaction Agreement") and the related Rule 2.7 Announcement under the Irish Takeover Rules. Terms used but not defined in this announcement have the same meaning given to them in the Transaction Agreement entered into between Alkermes and Avadel (the "Transaction Agreement") and the related Rule 2.7 Announcement…
PR Newswire
14/11/2025
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for…
Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetesRecommendation based on the TN-10 study, demonstrating Teizeild’s ability to delay the onset of stage 3 type 1 diabetes (T1D), compared to placebo, in adults and children with stage 2 T1DIf approved, Teizeild would become the first disease-modifying T1D therapy in the EU Paris,November 14,2025.The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use...
Nasdaq GlobeNewswire
14/11/2025
Orion receives award for international growth from the President of the Republic…
ORION CORPORATIONPRESS RELEASE14 NOVEMBER 2025 at 13.30 EET Orion receives award for international growth from the President of the Republic of FinlandToday, the President of the Republic of Finland,Alexander Stubb, has awarded Orion Corporation the Internationalisation Award of the President in the growth companies category.The Internationalisation Awards of the President of the Republic of Finland are bestowed annually in recognition of internationally successful...
Nasdaq GlobeNewswire
14/11/2025
Mom's Garden Showcases at CIIE, Gaining Traction in Chinese Market
"We are incredibly impressed by Chinese consumers' focus on clinically-proven evidence and high standards for quality," said Olga Stepanko, Global Brand Manager at Mom's Garden. "The CIIE is a great platform for connecting Germany's scientific expertise with the specific demands of the Chinese market. We look forward to expanding collaboration in health and nutrition to deliver product innovation grounded in solid scientific research." "We are incredibly impressed by…
PR Newswire
14/11/2025
Lundbeck files for marketing authorization across key Asian markets for Vyepti®…
"The acceptance of these regulatory applications signifies a critical milestone in Lundbeck's Asian development program for eptinezumab." said Johan Luthman, EVP and Head of Research and Development at Lundbeck. "Eptinezumab has the potential to fulfil a significant unmet need in Asia, where migraine preventive treatments remain underutilized. The eptinezumab global roll-out also paves the way for advancing additional migraine and neuro-rare programs to patients." "The…
PR Newswire
14/11/2025
Medicxi Announces €500 Million Fund V
Medicxi has created 16 new companies, delivered over 20 positive clinical data readouts and has realised over $1 billion across its portfolio since its last fundraise, including from investments in Vaxcyte, Merus and Abivax, and the acquisitions of ViceBio (Sanofi), Versanis Bio (Eli Lilly) and ProfoundBio (Genmab). Medicxi has created 16 new companies, delivered over 20 positive clinical data readouts and has realised over$1 billionacross its portfolio since its last fundraise, including...
PR Newswire
14/11/2025
Lumenis Launches OptiLIFT, a New Dynamic Muscle Stimulation Device, in the U.K.
Lower lid laxity is highly prevalent and is associated with the natural aging process, caused in part by the weakening of the orbicularis oculi muscle (OOM).1 Skeletal muscles lose 3-8% mass each decade after age 30.1 Muscle weakening in the periorbital area reduces structural support, which can result in lower lid laxity and incomplete blinking, leading to ocular symptoms and aesthetic concerns.2,3,4 One study revealed that more than 60% of dry eye patients suffer from impaired lid closure. ...
PR Newswire
14/11/2025
Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears last safety review…
"The continued favorable safety profile demonstrated in DIAGNODE-3 and earlier studies reinforces Diamyd's position as a leading precision medicine candidate in Type 1 Diabetes," says Professor Johnny Ludvigsson, Coordinating Investigator of DIAGNODE-3. "The continued favorable safety profile demonstrated in DIAGNODE-3 and earlier studies reinforces Diamyd's position as a leading precision medicine candidate in Type 1 Diabetes," says ProfessorJohnny Ludvigsson, Coordinating…
PR Newswire
14/11/2025
Bioxodes presents BIOX-101 clinical data showing breakthrough potential for…
Prof Lemmens underscores large unmet medical need in intracerebral hemorrhage “Very encouraging” data from Phase 2a trial with lead asset BIOX-101 Bioxodes is preparing for a possibly registrational Phase 2b trial, could bring BIOX-101 to market by late 2030 Gosselies, Belgium, 14 November 2025 (08:30 am CET)– Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, has held a...
Nasdaq GlobeNewswire
14/11/2025
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Nov.14, 2025(GLOBE NEWSWIRE) --Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDateNumber of SharesOutstandingTotal number of voting rightsTotal voting rights,...
Nasdaq GlobeNewswire
14/11/2025
Bavarian Nordic Announces Interim Results for the First Nine Months of 2025
COPENHAGEN, Denmark, November 14, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2025 and business progress for the third quarter of 2025. Revenue for the first nine months increased by 32% to DKK 4,793 million, reflecting a strong performance in both Travel Health and Public Preparedness.Travel Health revenue increased by 23% to DKK 2,327 million compared to the first nine months of 2024, primarily driven by increased...
Nasdaq GlobeNewswire
14/11/2025
German Women's Wellness Brand Princess Luna Presents at CIIE, Showcasing…
During the expo, Princess Luna presented its core product lines designed to support women's microbiological balance and overall well-being. The brand invited health professionals to introduce the science behind protecting women's health and address common misconceptions. During the expo,Princess Lunapresented its core product lines designed to support women's microbiological balance and overall well-being. The brand invited health professionals to introduce the science behind protecting...
PR Newswire
14/11/2025
From Furniture to Illumination: Tribesigns Launches Comprehensive Home Lighting…
Tribesigns' newly launched lighting collection features a rich and diverse assortment, including flush mount lights, chandeliers, pendants, lamps, vanity lights, sconces, ceiling fans, and outdoor wall lights. Together, these designs illuminate every corner of the home, casting a warm, gentle glow reminiscent of spring sunlight. Tribesigns' newly launched lighting collection features a rich and diverse assortment, including flush mount lights, chandeliers, pendants, lamps, vanity lights,...
PR Newswire
14/11/2025
Laboratory Centrifuges Market worth $1.86 billion by 2030 with 2.8% CAGR |…
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197749088 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197749088 Browse in-depth TOC on "Laboratory Centrifuges Market" 430 - Tables55 - Figures 350 - Pages By product,the laboratory centrifuges market is segmented into equipment and accessories. In 2025, the equipment segment holds the largest share of the market. Demand for laboratory centrifuge...
PR Newswire
14/11/2025
Amorepacific Named CES Innovation Award Honoree for Advanced Electronic Skin…
SEOUL, South Korea, Nov. 14, 2025 /PRNewswire/ -- Amorepacific has been named CES 2026 Innovation Award Honoree in the Beauty Tech category for its Skinsight™ technology, marking the company's seventh consecutive year of recognition at the CES Innovation Awards. SEOUL, South Korea , Nov. 14, 2025 /PRNewswire/ -- Amorepacific has been named CES 2026 Innovation Award Honoree in the Beauty Tech category for its Skinsight™ technology, marking the company's seventh consecutive year of...
PR Newswire
14/11/2025
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S…
INSIDE INFORMATION REGULATED INFORMATIONCorrection and ReplacementNyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of GenioFinancings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond. This press release replaces the press release issued on November 13, 2025, at 10:11 pm CET / 4:11 pm ET in order to replace and correct the gross proceeds of the...
Nasdaq GlobeNewswire
14/11/2025
Leqembi® approved for IV maintenance treatment in the United Kingdom
In the United Kingdom, an estimated 982,000 people are living with dementia,[2] with AD accounting for an estimated 60-70% of cases.[3] These numbers are expected to rise as the population ages. In theUnited Kingdom, an estimated 982,000 people are living with dementia, [2]with AD accounting for an estimated 60-70% of cases. [3] These numbers are expected to rise as the population ages. Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody...
PR Newswire
14/11/2025
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
Bagsværd, Denmark, 13 November 2025– Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as otherwise announced in the notice convening the Extraordinary General Meeting.Earlier today, Mikael Dolsten, who most recently served as the Head of R&D at Pfizer, informed Novo Nordisk that, in spite of his desire to join, he has decided to withdraw his candidacy to the Novo Nordisk...
Nasdaq GlobeNewswire
13/11/2025
Altri Comunicati
